Erica S. Klaassen - Concepedia

Author

Erica S. Klaassen

Also Known As

E Klaassen, E. Klaassen, E. S. Klaassen, E.N. Klaassen, E.S. Klaassen, Erica Klaassen, Erica S Klaassen, Erica S. Klaassen, Erica Surya Klaassen, Klaassen, E

Publications

945

Citations

H-Index

Concepts

All Affiliations

Centre for Human Drug Research Leiden University Medical Center Leiden University Amsterdam University Medical Centers Erasmus University Rotterdam

About

Erica S. Klaassen is an author at Centre for Human Drug Research specializing in medicine, pharmacology, and neurology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	285
2	Immunology	2	2	122
3	Health Sciences	1	1	78
4	Social Sciences	1	1	50
5	Diabetes	1	1	21

Erica S. Klaassen

Publications

868

Citations

H-Index

Page 1

	Year	Citations
IMO-8400, a toll-like receptor 7, 8, and 9 antagonist, demonstrates clinical activity in a phase 2a, randomized, placebo-controlled trial in patients with moderate-to-severe plaque psoriasis Deepak M.W. Balak, Martijn B. A. van Doorn, Robert D. Arbeit, Clinical Immunology InflammationToll-like Receptor 7Anti-inflammatoryAutoimmune DiseaseMedicine	2016	93
Effects on Spasticity and Neuropathic Pain of an Oral Formulation of Δ9-tetrahydrocannabinol in Patients With Progressive Multiple Sclerosis Guido van Amerongen, Kawita M. S. Kanhai, Anne Catrien Baakman, Clinical Therapeutics Cannabis UsePain DisordersNeurological AssessmentHealth SciencesPain Medicine	2017	78
Cholinergic and serotonergic modulation of resting state functional brain connectivity in Alzheimer's disease Bernadet L. Klaassens, Joop van Gerven, Erica S. Klaassen, NeuroImage NeuropsychologyBrain FunctionNeurophysiological BiomarkersVoxelwise Network ConnectivitySocial Sciences	2019	50
Does olanzapine inhibit the psychomimetic effects of Δ<sup>9</sup>-tetrahydrocannabinol? Daniël Kleinloog, M Liem-Moolenaar, Gabriël E. Jacobs, Journal of Psychopharmacology	2012	46
OX40L Inhibition Suppresses KLH‐driven Immune Responses in Healthy Volunteers: A Randomized Controlled Trial Demonstrating Proof‐of‐Pharmacology for KY1005 Mahdi Saghari, Pim Gal, Sally Gilbert, Clinical Pharmacology & Therapeutics	2022	44
A randomized controlled proof‐of‐concept trial of digoxin and furosemide in adults with cutaneous warts M. Rijsbergen, Tessa Niemeyer‐van der Kolk, G. Hogendoorn, British Journal of Dermatology	2018	37
First Clinical Study with AP30663 ‐ a K<sub>Ca</sub>2 Channel Inhibitor in Development for Conversion of Atrial Fibrillation Pim Gal, Erica S. Klaassen, Kirsten R. Bergmann, Clinical and Translational Science	2020	34
NS11821, a partial subtype-selective GABA<sub>A</sub> agonist, elicits selective effects on the central nervous system in randomized controlled trial with healthy subjects Rob Zuiker, Xia Chen, Ole Østerberg, Journal of Psychopharmacology	2015	29
Glutathione‐PEGylated liposomal methylprednisolone in comparison to free methylprednisolone: slow release characteristics and prolonged lymphocyte depression in a first‐in‐human study Kawita M. S. Kanhai, Rob Zuiker, I. Stavrakaki, British Journal of Clinical Pharmacology ImmunologyPharmacotherapyGlucocorticoidTranslational PharmacologyPre-clinical Pharmacology	2018	29
Relationships Between Type 2 Diabetes, Neuropathy, and Microvascular Dysfunction: Evidence From Patients With Cryptogenic Axonal Polyneuropathy Anna L. Emanuel, Mariska D. Nieuwenhoff, Erica S. Klaassen, Diabetes Care	2017	24

Page 1